Exeliom Biosciences: a new generation of microbiota-derived biotherapies
… the tumour, only 20% to 30% of cancer patients achieve a durable response to current treatments. To overcome this … a specific bacterium, Faecalibacterium prausnitzii (Fprau), was consistently absent in patients experiencing a relapse … by support from Bpifrance (I-Lab, Deep tech, 2030 Recovery Plan) and the H2020 programme, a highly selective European …
Published on: